Open an account

Cibus

CBUS · NASDAQ

$1.39+$0.08 (+6.11%)TodayMarket closed ·
Prev close $1.31

About CBUS

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 118 full-time employees. The company went IPO on 2017-07-20. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits. The company has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.

Employees
118
Headquarters
San Diego, California
Listed
Jul 20, 2017
Sector
Health Care
Industry
Biotechnology
Website
cibus.com

CBUS key statistics

Market cap
106.24M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
119.69K
Volume
56.95K
Open price
$1.33
High today
$1.45
Low today
$1.32
52 Week high
$4.19
52 Week low
$1.09

Cibus (CBUS) at a glance

Cibus (CBUS) last traded at $1.39, with a market cap of 106.24M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.32 and $1.45. The current price is 5.3% above the day's low and 4.1% below its high.

Volume so far is 56.95K shares, below the average of 119.69K shares a day.

Over the past year Cibus has ranged from $1.09 to $4.19, and now sits 10% of the way up that range.

Cibus met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.29 per share against an estimate of -$0.2652.

The average analyst price target is $14.28, 927.3% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 4 analystsAvg $14.28
Low
$3.03
Now
$1.39
High
$26.25

CBUS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 35.0% on average.

  1. Q3 FY24: reported $0.06 per share against an estimate of -$0.9129
  2. Q4 FY24: reported -$0.87 per share against an estimate of -$0.7701
  3. Q1 FY25: reported -$0.74 per share against an estimate of -$0.6732
  4. Q2 FY25: reported -$0.61 per share against an estimate of -$0.7072
  5. Q3 FY25: reported -$0.44 per share against an estimate of -$0.5338
  6. Q4 FY25: reported -$0.59 per share against an estimate of -$0.4386
  7. Q1 FY26: reported -$0.33 per share against an estimate of -$0.3366
  8. Q2 FY26: reported -$0.29 per share against an estimate of -$0.2652

CBUS news

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseGlobe Newswire

    Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call

  • Cibus Q1 2026 Earnings Call: Complete Transcript

  • Press releaseGlobe Newswire

    Cibus to Report First Quarter 2026 Financial Results on May 14, 2026 After the Market Close and Host Conference Call

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

Similar companies

Companies in the same industry as Cibus

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.